Lydia S Lamb1,2, Helman Alfonso3, Paul E Norman1, Timothy M E Davis1,2, Josephine Forbes4, Gerald Müench5, Felix Irrgang5, Osvaldo P Almeida1,6, Jonathan Golledge7,8, Graeme J Hankey1, Leon Flicker1,6, Bu B Yeap1,2. 1. Medical School, University of Western Australia, Perth, Western Australia, Australia. 2. Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western Australia, Australia. 3. School of Population Health, Curtin University, Perth, Western Australia, Australia. 4. Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia. 5. School of Medicine, Western Sydney University, Sydney, New South Wales, Australia. 6. WA Centre for Health & Ageing, Centre for Medical Research, Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia. 7. Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia. 8. Department of Vascular and Endovascular Surgery, Townsville Hospital, Townsville, Queensland, Australia.
Abstract
Background: Diabetes mellitus is associated with increased fracture risk despite preservation of bone density and reduced bone turnover. Aims: We tested the hypothesis that circulating advanced glycation end products (AGEs) and endogenous secretory receptor for AGEs (esRAGE) differentially modulate bone turnover and predict fracture risk in older men. Participants: A total of 3384 community-dwelling men aged 70 to 89 years. Methods: Collagen type I C-terminal cross-linked telopeptide, N-terminal propeptide of type I collagen (P1NP), and total osteocalcin (TOC) were assayed using immunoassay and undercarboxylated osteocalcin (ucOC) following hydroxyapatite binding. Plasma N-carboxymethyllysine (CML) and esRAGE were assayed using immunoassay. Methylglyoxal and glyoxal were assayed using mass spectrometry. Incident hip fractures were ascertained. Results: Median age was 76.3 years (interquartile range, 74.2 to 79.1 years). Plasma CML was measured in 3011 men, methylglyoxal and glyoxal in 766 men, and esRAGE in 748 men. Plasma CML, methylglyoxal, glyoxal, and esRAGE were similar in men without and with diabetes (all P > 0.05). CML was positively associated with fasting glucose (r = 0.06, P < 0.001), and esRAGE was inversely associated (r = -0.08, P = 0.045). esRAGE was positively associated with bone formation (P1NP, r = 0.17, P < 0.001; ucOC, r = 0.11, P = 0.008; TOC, r = 0.16, P < 0.001). Incident hip fractures occurred in 106 men during follow-up. Men with CML in the third quartile of values had reduced incidence of hip fracture compared with men in the lowest quartile (hazard ratio, 0.49; 95% CI, 0.24 to 0.99; P = 0.045). Conclusions: Glycemia associates positively with CML and reciprocally with esRAGE in older men. Circulating esRAGE modulates bone turnover in older men, whereas CML predicts incidence of hip fracture.
Background: Diabetes mellitus is associated with increased fracture risk despite preservation of bone density and reduced bone turnover. Aims: We tested the hypothesis that circulating advanced glycation end products (AGEs) and endogenous secretory receptor for AGEs (esRAGE) differentially modulate bone turnover and predict fracture risk in older men. Participants: A total of 3384 community-dwelling men aged 70 to 89 years. Methods: Collagen type I C-terminal cross-linked telopeptide, N-terminal propeptide of type I collagen (P1NP), and total osteocalcin (TOC) were assayed using immunoassay and undercarboxylated osteocalcin (ucOC) following hydroxyapatite binding. Plasma N-carboxymethyllysine (CML) and esRAGE were assayed using immunoassay. Methylglyoxal and glyoxal were assayed using mass spectrometry. Incident hip fractures were ascertained. Results: Median age was 76.3 years (interquartile range, 74.2 to 79.1 years). Plasma CML was measured in 3011 men, methylglyoxal and glyoxal in 766 men, and esRAGE in 748 men. Plasma CML, methylglyoxal, glyoxal, and esRAGE were similar in men without and with diabetes (all P > 0.05). CML was positively associated with fasting glucose (r = 0.06, P < 0.001), and esRAGE was inversely associated (r = -0.08, P = 0.045). esRAGE was positively associated with bone formation (P1NP, r = 0.17, P < 0.001; ucOC, r = 0.11, P = 0.008; TOC, r = 0.16, P < 0.001). Incident hip fractures occurred in 106 men during follow-up. Men with CML in the third quartile of values had reduced incidence of hip fracture compared with men in the lowest quartile (hazard ratio, 0.49; 95% CI, 0.24 to 0.99; P = 0.045). Conclusions: Glycemia associates positively with CML and reciprocally with esRAGE in older men. Circulating esRAGE modulates bone turnover in older men, whereas CML predicts incidence of hip fracture.
Authors: Ruban Dhaliwal; Susan K Ewing; Deepak Vashishth; Richard D Semba; Ann V Schwartz Journal: J Bone Miner Res Date: 2021-11-24 Impact factor: 6.741
Authors: A P Jarrete; L T Giollo-Junior; J F Vilela-Martin; I P Novais; M A Delbin; A Zanesco Journal: Braz J Med Biol Res Date: 2022-02-28 Impact factor: 2.590
Authors: Komal Waqas; Jinluan Chen; Fjorda Koromani; Katerina Trajanoska; Bram Cj van der Eerden; André G Uitterlinden; Fernando Rivadeneira; M Carola Zillikens Journal: J Bone Miner Res Date: 2020-06-22 Impact factor: 6.741
Authors: Komal Waqas; Jinluan Chen; Bram C J van der Eerden; M Arfan Ikram; André G Uitterlinden; Trudy Voortman; M Carola Zillikens Journal: Nutrients Date: 2020-08-08 Impact factor: 5.717